Cyclin-dependent kinase inhibitors: efficacy and safety

Cyclin-dependent kinase inhibitors: efficacy and safety

Breast Cancer is the most common type of cancer worldwide. Scientific advances and new ways of treating have significantly improved the prognosis of breast cancer in recent decades. The emergence of modern cyclin-dependent kinase (CDK) inhibitors has changed the treatment paradigm for metastatic hor...

Full description

Bibliographic Details
Main Authors:	I. B. Kononenko, A. V. Snegovoi, V. Yu. Selchuk
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2019-06-01
Series:	Медицинский совет
Subjects:	metastatic breast cancer cyclin-dependent kinases cyclin-dependent kinase 4 and 6 inhibitors efficiency side effects
Online Access:	https://www.med-sovet.pro/jour/article/view/3052

Similar Items

Induction of apoptosis in cancer cells by tumor necrosis factor and butyrolactone, an inhibitor of cyclin-dependent kinases
by: J.E. Belizário, et al.
Published: (1999-04-01)

Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases
by: Mark Klein
Published: (2023-03-01)

Correlation of serum concentration cyclin-dependent kinase 4 and cyclin-dependent kinase 6 with breast cancer in Babylon province
by: Dalya Shakir Al-Owaidi, et al.
Published: (2020-01-01)

Expression of cyclooxygenase-2(COX-2) and cyclin dependent kinase 1B (CDKN1B/p27Kip1⁯) in human prostatet adenocarcinoma
by: Md Roduan, Mohd Rohaizad
Published: (2011)

Efficacy and safety of cyclin‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience
by: Tzu‐Rong Peng, et al.
Published: (2023-10-01)

Sub-cloning of cyclin-dependent kinase 3 (CDK3) gene into a mammalian expression vector /
by: Alnaseri, Zubaida Talal M., 1996-, author 614711
Published: (2018)

Sub-cloning of cyclin-dependent kinase 3 (CDK3) gene into a mammalian expression vector /
by: Alnaseri, Zubaida Talal M., 1996-, author 614711, et al.
Published: (2018)

A review on the role of cyclin dependent kinases in cancers
by: Soudeh Ghafouri-Fard, et al.
Published: (2022-10-01)

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
by: Pauline Rottier, et al.
Published: (2023-01-01)

The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
by: Aadil Javed, et al.
Published: (2023-02-01)

Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer
by: L. Bender, et al.
Published: (2023-01-01)

Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma
by: Selami Koçak Toprak, et al.
Published: (2012-03-01)

Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation
by: Yanting Zhou, et al.
Published: (2023-05-01)

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
by: Paweł Łukasik, et al.
Published: (2021-03-01)

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
by: Paweł Łukasik, et al.
Published: (2021-03-01)

Generation of knockout mouse models of cyclin-dependent kinase inhibitors by engineered nuclease-mediated genome editing
by: Bo Min Park, et al.
Published: (2018-12-01)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
by: Navid Sobhani, et al.
Published: (2019-04-01)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
by: Hasan Çağrı Yıldırım, et al.
Published: (2022-12-01)

Cyclin B Export to the Cytoplasm via the Nup62 Subcomplex and Subsequent Rapid Nuclear Import Are Required for the Initiation of <i>Drosophila</i> Male Meiosis
by: Kanta Yamazoe, et al.
Published: (2023-11-01)

Lappaol F regulates the cell cycle by activating CDKN1C/p57 in human colorectal cancer cells
by: Rui-Yi Yang, et al.
Published: (2023-12-01)

ASSOCIATION OF RS2069502 CYCLIN-DEPENDENT KINASE 4 GENE WITH BREAST CANCER
by: Dalya Shakir Al-owaidi
Published: (2020-04-01)

Design, Synthesis, and Activity Assays of Cyclin-Dependent Kinase 1 Inhibitors With Flavone Scaffolds
by: Lanlan Fu, et al.
Published: (2022-08-01)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
by: Emanuel Raschi, et al.
Published: (2021-04-01)

A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer
by: Pin Zhang, et al.
Published: (2021-04-01)

Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A Review of the Literature
by: Rejane Franco, et al.
Published: (2023-06-01)

Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes
by: Lifei Wang, et al.
Published: (2023-12-01)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
by: David Howard, et al.
Published: (2022-11-01)

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors
by: Mariane Teodoro Fernandes, et al.
Published: (2018-11-01)

The kinome, cyclins and cyclin-dependent kinases of pituitary adenomas, a look into the gene expression profile among tumors from different lineages
by: Keiko Taniguchi-Ponciano, et al.
Published: (2022-03-01)

Multiple cutaneous melanomas associated with gastric and brain metastases
by: Lara Caroline Grander, et al.
Published: (2016-10-01)

Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
by: S. F. Menshikova, et al.
Published: (2018-11-01)

Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
by: Isabella O. Wender, et al.
Published: (2020-09-01)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
by: Alessia Schirripa, et al.
Published: (2022-08-01)

Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma
by: Yu-Yun Shao, et al.
Published: (2019-09-01)

Immunohistochemical Expression of p27<sup>Kip1</sup>, p57<sup>Kip2</sup>, Cyclin D1, Nestin, and Ki-67 in Ependymoma
by: Shahad Iqneibi, et al.
Published: (2022-02-01)

Mouse Model of Congenital Heart Defects, Dysmorphic Facial Features and Intellectual Developmental Disorders as a Result of Non-functional CDK13
by: Monika Nováková, et al.
Published: (2019-08-01)

Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
by: Sandeep Kumar Parvathareddy, et al.
Published: (2021-05-01)

Exploring cell cycle-mediated regulations of glycolysis in budding yeast
by: Yanfei Zhang, et al.
Published: (2023-10-01)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
by: Rossana Roncato, et al.
Published: (2020-09-01)

The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
by: Balbina García-Reyes, et al.
Published: (2018-10-01)